Table 1.
Baseline characteristics of the study population.
| Inactive N = 50 |
Active N = 107 |
P value | |
|---|---|---|---|
| Age (yrs.) | 53.8 ± 13.8 | 51.4 ± 12.4 | 0.321 |
| BMI (kg/m2) | 25.1 ± 4.1 | 24.9 ± 4.5 | 0.396 |
| Dominance (RT) | 42 (84.0%) | 94 (87.9%) | 0.335 |
| Smokers | 11 (22.0%) | 13 (12.1%) | 0.089 |
| Hospital stay (days) | 1.6 ± 0.8 | 1.5 ± 0.7 | 0.850 |
| Surgical treatments | |||
| Mastectomy | 16 (32.0%) | 39 (36.4%) | 0.360 |
| Lumpectomy | 34 (68.0%) | 68 (63.6%) | |
| ALNB | 7 (14.0%) | 7 (6.5%) | 0.164 |
| SLNB | 43 (86.0%) | 97 (90.7%) | |
| Reconstruction | 15 (30.0%) | 40 (37.4%) | 0.236 |
| Non-surgical treatments | |||
| Neoadjuvant. C | 17 (34.0%) | 18 (16.8%) | 0.023* |
| Chemotherapy | 24 (48.0%) | 36 (33.6%) | 0.061 |
| Radiation therapy | 40 (80.0%) | 56 (52.3%) | < 0.001* |
| Number of sick days | |||
| 1–7 | 4 (8.0%) | 12 (11.2%) | 0.901 |
| 8–14 | 7 (14.0%) | 13 (12.1%) | |
| 15–21 | 13 (26.0) | 26 (24.3%) | |
| 22–30 | 6 (12.0%) | 18 (16.8%) | |
| More than 30 | 16 (32.0%) | 32 (29.9%) | |
| Postoperative complications | |||
| Infection | 5 (10.0%) | 6 (5.6%) | 0.317 |
| Seroma | 5 (10.0%) | 6 (5.6%) | 0.317 |
| Revision surgery | 3 (6.0%) | 1 (1.0%) | 0.061 |
| AWS (6 MNTH) | 2 (4.1%) | 14 (13.1%) | 0.081 |
| Lymphedema (6 MNTH) | 6 (12.2%) | 6 (5.7%) | 0.334 |
Continuous variables are presented as mean and standard deviation (SD) and categorical variables are presented as number and percentage. Significant p value*p ≤ 0.05.
YRS, Years; BMI, Body mass index; kg/m2, Mass in kilograms divided by the square of the body height in meters; RT, Right; Neoadjuvant. C, Neoadjuvant Chemotherapy; ALND, Axillar lymph node dissection; SLNB, Sentinel lymph node biopsy; BRCA1-2, Breast Cancer gene; NPRS, Numeric pain rating scale; AWS, Axillar web syndrome; MNTH, Month.